Our Pipeline

Translating cutting-edge science into breakthrough therapeutics

Pipeline

Development Pipeline

Discovery
Preclinical Validation
Lead Optimization
Ind-enabling
Phase I
Phase II/III
PST010
Oncology
Stage: Lead Optimization
Ena/VASP (PPI)
In-house
collaboration

The fundamental cancer driver Ena/VASP acts as a crucial hub for tumor cell migration and is highly upregulated in invasive cancer forms.

Neoangiogenesis
Metastasis
Protein-protein interaction
Solid tumors
New mode of action
PST020
Infectious Diseases
Stage: Lead Optimization
Target Undisclosed (PPI)
In-house
collaboration

This target is currently undisclosed.

Emerging infectious diseases
Bacterial pathogenesis
PST030
Oncology
Stage: Discovery
Target of Choice (PPI)
In-house
collaboration

This target is currently undisclosed.

Cell growth and proliferation
New mode of action
Solid tumors
PST040
CNS
Stage: Discovery
Target of Choice (PPI)
In-house
collaboration

This target is currently undisclosed.

Neurodegeneration
Neuropathology
Signal transduction

PIPELINE | ONCOLOGY

Aiming to improve survival rates for the most lethal tumor forms, we primarily strive to develop novel and universal cancer therapies.

PIPELINE | Beyond Oncology

While we focus on oncology in-house, we aim to fully utilize our platform’s potential and build a diversified portfolio of assets with strong partners on our side.

Cardiovascular Diseases

Infectious Diseases

Neurodegenerative Disease

Further Diseases